← Critical Product/Equipment/Process: Chemicals, Pharma & Process (all topics)
Contract manufacturing - fluorinated molecules (CDMO)
What it is
Contract development and manufacture of fluorinated intermediates and active ingredients for pharmaceutical and agrochemical innovators. Fluorine is present in a large share of modern drug and crop-protection molecules because it improves stability and potency
The innovator owns the molecule; the Indian partner owns the fluorination capability
Impact on industries
- Fluorination is specialised and hazardous, so few contract manufacturers can do it - the competitive set is far narrower than in general CDMO work
- Multi-year contracts priced on capability rather than commodity spread, and insulated from the refrigerant and industrial cycles
- China-plus-one sourcing has widened the opportunity, since innovators want a second qualified fluorination base
- Customer and molecule concentration is severe - a patent expiry or clinical failure removes a revenue line with no substitute demand
- Requires captive AHF, dedicated plants and sustained qualification investment before any revenue